Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 48, Issue 2, 2000, Pages 89-94

  Kraus, J A ^a   Glesmann, N ^a   Beck, M ^a   Krex, D ^b   Klockgether, T ^a   Schackert, G ^b   Schlegel, U ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

CDKN2A; Glioblastoma multiforme; Long term survival; PTEN; TP53; Tumor suppressor gene

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; NITROSOUREA; PROTEIN MDM2; PROTEIN P53;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT NEOPLASTIC DISEASE; PROGNOSIS; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL TIME; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADULT; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE DELETION; GENES, P16; GENES, P53; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PHOSPHORIC MONOESTER HYDROLASES; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; POSTOPERATIVE PERIOD; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SUPRATENTORIAL NEOPLASMS; SURVIVAL ANALYSIS; SURVIVORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0033772866     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006402614838     Document Type: Article

References (45)

1. Tumours of the nervous system
2. Effects of treatment on long-term survivors with malignant astrocytomas
3. Treatment of malignant glioma in adults
4. Ten-year survival among patients with supratentorial astrocytomas grade III and IV
5. Long-term survival in patients with glioblastoma multiforme
6. Long-term survivors of glioblastoma multiforme: Clinical and molecular characteristics
7. Long-term glioblastoma multiforme survivors: A population-based study
8. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials
9. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome
10. Progression as exemplified by human astrocytic tumors
11. Molecular pathogenesis of malignant gliomas
12. p53, the cellular gatekeeper for growth and division
13. Functions of the MDM2 oncoprotein
14. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations
15. PTEN mutations in gliomas and glioneuronal tumors
16. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: Relationship to prognostic significance
17. Malignant astrocytomas with homozygous CDKN2 gene deletions have higher Ki-67 proliferation indices
18. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme
19. Histological typing of tumors of the central nervous system
20. TP53 alterations and clinical outcome in low grade astrocytomas
21. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma
22. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification
23. Lack of prognostic relevance of alterations in the epidermal growth factor receptor - Transforming growth factor-alpha pathway in human astrocytic gliomas
24. Malignant glioma: Who benefit from adjuvant chemotherapy?
25. Long-term survival after the diagnosis of malignant glioma: A series of 22 patients surviving more than 4 years after diagnosis
26. Long-term survival in patients with malignant astrocytoma
27. Long-term malignant glioma survivors over ten years: Prognostic factors
28. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperation Oncology Group study
29. Survival after stereotactic biopsy of malignant gliomas
30. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma
31. Early postoperative magnetic resonance imaging after resection of malignant glioma: Objective evaluation of residual tumor and its influence on regrowth and prognosis
32. Clinically distinct subgroups of glioblastoma multiforme studied by comparative genomic hybridization
33. Gene amplification as a rognostic factor in primary and secondary high-grade malignant gliomas
34. Tumor suppressor gene alterations in malignant gliomas: Histopathological associations and prognostic evaluation
35. PTEN gene mutations are seen in high-grade but not in low-grade gliomas
36. Somatic mutations of PTEN in glioblastoma multiforme
37. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.
38. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts
39. High p53 expression is prognostic of overall survival in adult supratentorial astrocytoma patients
40. The p53 gene and protein in human brain tumors
41. Alterations of the TP53 gene in human gliomas
42. Genetic sub-types of human malignant astrocytoma correlate with survival
43. Primary and secondary glioblastomas: From concept to clinical diagnosis
44. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas
45. CDKN2 or RB alterations occur in the majority of glioblastomas and are inversely related